NASDAQ:AKBA - Akebia Therapeutics Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$5.57 -0.03 (-0.54 %)
(As of 05/23/2019 06:37 AM ET)
Previous Close$5.60
Today's Range$5.4001 - $5.65
52-Week Range$5.20 - $11.60
Volume681,409 shs
Average Volume1.01 million shs
Market Capitalization$656.48 million
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

Akebia Therapeutics (NASDAQ:AKBA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 164.81%. The high price target for AKBA is $22.00 and the low price target for AKBA is $9.00. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.572.672.75
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.75$15.1429$16.1667$20.00
Price Target Upside: 164.81% upside86.95% upside91.78% upside146.91% upside

Akebia Therapeutics (NASDAQ:AKBA) Consensus Price Target History

Price Target History for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$12.00HighView Rating Details
3/20/2019CitigroupInitiated CoverageNeutral ➝ Neutral$9.00HighView Rating Details
12/4/2018MizuhoReiterated RatingBuy$17.00MediumView Rating Details
9/7/2018Morgan StanleyInitiated CoverageEqual ➝ WeightHighView Rating Details
8/13/2018Raymond JamesInitiated CoverageBuy$18.00MediumView Rating Details
8/10/2018Needham & Company LLCLower Price TargetBuy$20.00 ➝ $18.00MediumView Rating Details
8/9/2018Royal Bank of CanadaReiterated RatingHold$13.00MediumView Rating Details
6/29/2018HC WainwrightReiterated RatingBuyHighView Rating Details
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$26.00MediumView Rating Details
12/7/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00MediumView Rating Details
6/30/2017AegisReiterated RatingBuyHighView Rating Details
(Data available from 5/23/2017 forward)
This page was last updated on 5/23/2019 by Staff

Featured Article: Convertible Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel